Skip to main content
GERN logo

GERN · Geron Corp

Track GERN — free
$1.47 -0.07 (-4.23%) At close · Aug 14
Market Cap
$944.44M
Shares
642.47M

Geron Corp Earnings Call Transcripts

Every quarterly earnings call for Geron Corp (GERN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-05
Q2 2026 Geron Earnings Conference Call
Confident tone Ritello commercial performance and demand growth Real-world evidence and medical engagement Phase 3 IMpactMS trial in myelofibrosis
Revenue
$57.48M
▲ 17.2% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Geron Corp Q1 FY2026 Earnings Call
Positive tone RYTELO U.S. commercial growth European commercial and pricing strategy Medical affairs / hematology engagement
Revenue
$51.84M
▲ 30.9% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-13
25th Annual Needham Virtual Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-10
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-25
Geron Corp Q4 FY2025 Earnings Call
Confident tone Rytelo commercial growth and second-line MDS opportunity 3D surround sound and field force execution 2026 financial guidance and path to profitability
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Geron Corp Q3 FY2025 Earnings Call
Positive tone RYTELO commercial performance and growth Healthcare provider awareness and education Commercial execution and strategy reset
Revenue
$47.23M
▲ 67.1% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Geron Corp Q2 FY2025 Earnings Call
Positive tone RYTELO U.S. commercial performance HCP awareness and earlier-line adoption EU launch and partnering strategy
Revenue
$49.04M
▲ 5459.6% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Geron Corp Q1 FY2025 Earnings Call
Positive tone RYTELO U.S. commercial launch IMPACT MS Phase 3 in myelofibrosis Commercial strategy enhancements
Revenue
$39.60M
▲ 12927.3% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Geron Corp Q4 FY2024 Earnings Call
Positive tone RYTELO commercial launch and revenue trends Myelofibrosis IMpactMF Phase 3 trial Duration of treatment
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Geron Corp Q3 FY2024 Earnings Call
Confident tone RYTELO U.S. Commercial Launch Performance Lower-Risk MDS Market Opportunity and Demand Financing Transactions and Capital Position
Revenue
$28.27M
▲ 17138.4% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Geron Corp Q2 FY2024 Earnings Call
Confident tone RYTELO commercial launch NCCN Guidelines inclusion Lower-risk MDS market opportunity
Revenue
$882,000
▲ 2941.4% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Geron Corp Q1 FY2024 Earnings Call
Confident tone U.S. Launch of Imetelstat in Lower-Risk MDS Market Differentiation and Unmet Need FDA / Regulatory Progress
Revenue
$304,000
▲ 1347.6% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Geron Corp Q4 FY2023 Earnings Call
Confident tone FDA regulatory review and ODAC IMerge Phase 3 clinical data in lower-risk MDS IMpactMF Phase 3 in myelofibrosis
Revenue
$23,000*
▼ 77.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Geron Corp Q3 FY2023 Earnings Call
Revenue
$164,000
▼ 44.8% YoY
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Geron Corp Q2 FY2023 Earnings Call
Revenue
$29,000
▼ 60.3% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-20
Geron Corp Q1 FY2023 Earnings Call
Revenue
$21,000
▼ 82.9% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Geron Corp Q4 FY2022 Earnings Call
Revenue
$103,000*
▼ 90.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Geron Corp Q3 FY2022 Earnings Call
Revenue
$297,000
▲ 172.5% YoY
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Geron Corp Q2 FY2022 Earnings Call
Revenue
$73,000
▼ 31.8% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-13
Geron Corp Q1 FY2022 Earnings Call
Revenue
$123,000
▼ 10.2% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Geron Corp Q4 FY2021 Earnings Call
Revenue
$1.04M*
▲ 1980% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Geron Corp Q3 FY2021 Earnings Call
Revenue
$109,000
▲ 0.9% YoY
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Geron Corp Q2 FY2021 Earnings Call
Revenue
$107,000
▲ 148.8% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Geron Corp Q1 FY2021 Earnings Call
Revenue
$137,000
▲ 163.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Geron Corp Q4 FY2020 Earnings Call
Revenue
$50,000*
▼ 70.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Geron Corp Q3 FY2020 Earnings Call
Revenue
$108,000
▼ 17.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Geron Corp Q2 FY2020 Earnings Call
Revenue
$43,000
▼ 57.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-28
Geron Corp Q1 FY2020 Earnings Call
Revenue
$52,000
▼ 8.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–29 of 29 earnings calls
Key facts CIK 886744 CUSIP 374163103 13F (30d) 250 filings 247 filers Visit website Investor relations